Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bommier

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Ethics, Medicine, and Public Health|September 8, 2021
Treating strangeness: Medicine and human dignity at the time of COVID-19C Hervé, A-M Duguet, C Georges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trialJean-Marie Michot, Serge Bologna, Jean-Noël Bastie, et al.
Blood Advances|September 25, 2024
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literatureCôme Bommier, Brian K Link, Brianna J Gysbers, et al.
Hematological Oncology|October 1, 2024
Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA studyC Bommier, M Donzel, C Rossi, et al.
Bone Marrow Transplantation|March 2, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Bone Marrow Transplantation|January 8, 2026
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohortAmélie Anota, Mathurine Basset, Emilie Charton, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Ethics, Medicine, and Public Health|September 8, 2021
Treating strangeness: Medicine and human dignity at the time of COVID-19C Hervé, A-M Duguet, C Georges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trialJean-Marie Michot, Serge Bologna, Jean-Noël Bastie, et al.
Blood Advances|September 25, 2024
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literatureCôme Bommier, Brian K Link, Brianna J Gysbers, et al.
Hematological Oncology|October 1, 2024
Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA studyC Bommier, M Donzel, C Rossi, et al.
Bone Marrow Transplantation|March 2, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Bone Marrow Transplantation|January 8, 2026
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohortAmélie Anota, Mathurine Basset, Emilie Charton, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Pageof 7